As of Feb 03, 2025, West Pharmaceutical Services, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $92.4. This suggests it may be overvalued by (72.6%) compared to its current price of around $337.0, using a WACC of 9.0% and growth rates of 3.0%.
As of Feb 03, 2025, West Pharmaceutical Services, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 9.0%.
As of Feb 03, 2025, West Pharmaceutical Services, Inc.'s Enterprise Value (EV) is approximately $6,182.3M. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.